宽大
发表于 2025-3-30 10:53:15
http://reply.papertrans.cn/67/6653/665297/665297_51.png
虚构的东西
发表于 2025-3-30 12:24:40
Takatoshi Sato,Hiroshi Suzuki,Taro Kusuyama,Yasutoshi Omori,Teruko Soda,Fumiyoshi Tsunoda,Makoto Sho
格子架
发表于 2025-3-30 19:34:17
Conference proceedings 2007w-derived progenitor cells. In addition to animal experiments, results of research on human tissues and organs are included. Researchers in the field will find this volume an invaluable source of reference in their work..
卡死偷电
发表于 2025-3-30 22:27:21
Liver regeneration with the resolution of fibrosis by bone marrow cell infusion therapysurvival rate. Recent our finding indicates that mesencymal bone marrow cells will differentiate to hepatocytes and FGF2 will accelerate this differentiation of BMC to hepatocyte. Based on the results obtained in basic research using the GFP/CCl. model, human trials are now undergoing.
无动于衷
发表于 2025-3-31 03:42:27
http://reply.papertrans.cn/67/6653/665297/665297_55.png
狂乱
发表于 2025-3-31 09:03:13
http://reply.papertrans.cn/67/6653/665297/665297_56.png
Prognosis
发表于 2025-3-31 09:39:58
TNF-α mobilizes bone marrow derived cells to vascular wall, resulting in neointima formation throughafter the injury, developed neointimal area was smaller in KO. Furthermore, re-endothelialization appeared earlier in KO than WT. Conclusion: TNF-α is involved in neointimal formation after vascular injury, possible through its inflammatory effects to induce bone marrow cells.
obligation
发表于 2025-3-31 17:18:59
Does PACAP have therapeutic potential in the field of neuroregenerative medicine?egies for the treatment of cerebrovascular disease. In particular, we will focus on the prospects of pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide that has been shown to exert both neuroprotective and neurogenic effects.
止痛药
发表于 2025-3-31 17:42:29
http://reply.papertrans.cn/67/6653/665297/665297_59.png
palliate
发表于 2025-4-1 00:01:17
Hepatocyte transplantation for liver diseaseindicate that Htx increases survival of acute liver failure patients and partially or completely corrects metabolic liver disease. These promising results suggest that Htx could be an inexpensive and effective treatment for liver disease. Clinical programs are now established in at least 13 different centers in 9 different countries.